High-rolling investors have positioned themselves bearish on Capricor Therapeutics (NASDAQ:CAPR), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in CAPR often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 10 options trades for Capricor Therapeutics. This is not a typical pattern.
The sentiment among these major traders is split, with 20% bullish and 70% bearish. Among all the options we identified, there was one put, amounting to $29,500, and 9 calls, totaling $529,340.
What's The Price Target?
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $7.5 to $30.0 for Capricor Therapeutics over the recent three months.
Analyzing Volume & Open Interest
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Capricor Therapeutics's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Capricor Therapeutics's significant trades, within a strike price range of $7.5 to $30.0, over the past month.
Capricor Therapeutics Call and Put Volume: 30-Day Overview
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CAPR | CALL | SWEEP | NEUTRAL | 01/15/27 | $6.8 | $5.6 | $5.6 | $17.50 | $154.5K | 281 | 376 |
| CAPR | CALL | TRADE | BEARISH | 01/15/27 | $6.9 | $6.0 | $6.0 | $17.50 | $60.0K | 281 | 700 |
| CAPR | CALL | TRADE | BEARISH | 01/15/27 | $6.6 | $5.6 | $5.6 | $17.50 | $56.0K | 281 | 576 |
| CAPR | CALL | TRADE | BEARISH | 01/15/27 | $6.6 | $5.6 | $5.6 | $17.50 | $56.0K | 281 | 476 |
| CAPR | CALL | TRADE | BEARISH | 01/15/27 | $6.8 | $5.6 | $5.6 | $17.50 | $56.0K | 281 | 0 |
About Capricor Therapeutics
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Current Position of Capricor Therapeutics
- With a trading volume of 1,289,638, the price of CAPR is up by 0.25%, reaching $11.81.
- Current RSI values indicate that the stock is may be approaching overbought.
- Next earnings report is scheduled for 51 days from now.
What The Experts Say On Capricor Therapeutics
1 market experts have recently issued ratings for this stock, with a consensus target price of $77.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * An analyst from HC Wainwright & Co. downgraded its action to Buy with a price target of $77.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Capricor Therapeutics with Benzinga Pro for real-time alerts.
Latest Ratings for CAPR
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 2025 | HC Wainwright & Co. | Reiterates | Buy | Buy |
| May 2025 | Cantor Fitzgerald | Reiterates | Overweight | Overweight |
| Mar 2025 | Cantor Fitzgerald | Reiterates | Overweight | Overweight |
View More Analyst Ratings for CAPR
View the Latest Analyst Ratings
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
